Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida Business Wire - Mon Jun 15, 5:00AM CDT

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience,...

JNJ : 228.39 (-2.48%)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma PR Newswire - Sat Jun 13, 5:33AM CDT

STOCKHOLM , June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study...

JNJ : 228.39 (-2.48%)
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients Business Wire - Thu Jun 11, 6:45AM CDT

Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. ...

JNJ : 228.39 (-2.48%)
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies PR Newswire - Thu Jun 11, 1:03AM CDT

STOCKHOLM , June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY ® (nipocalimab-aahu) produced a...

JNJ : 228.39 (-2.48%)
Biotech research by Gorodenkoff via Shutterstock
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results Barchart - Tue Jun 9, 8:29AM CDT

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 31.23 (-0.10%)
JNJ : 228.39 (-2.48%)
INCY : 98.22 (-0.78%)
TNGX : 27.97 (-13.38%)
RHHBY : 49.7400 (-2.59%)
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform Business Wire - Mon Jun 8, 7:00AM CDT

Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader antibody conjugate...

JNJ : 228.39 (-2.48%)
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study PR Newswire - Tue Jun 2, 11:04PM CDT

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index...

JNJ : 228.39 (-2.48%)
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease PR Newswire - Tue Jun 2, 11:03PM CDT

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe...

JNJ : 228.39 (-2.48%)
A concept image of weight-loss pills and a measuring tape by Artem Stepanov via Shutterstock
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF Barchart - Tue Jun 2, 2:02PM CDT

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

IHE : 91.88 (-1.02%)
JNJ : 228.39 (-2.48%)
LLY : 1,098.57 (-1.21%)
PPH : 102.53 (-1.64%)
$DOWI : 51,564.70 (unch)
MarketBeat.com
3 Dividend Kings That Earn Their Crown Every Quarter MarketBeat - Sun May 31, 8:25AM CDT

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

JNJ : 228.39 (-2.48%)
BDX : 143.98 (+1.67%)
KVUE : 18.12 (+0.61%)
PEP : 142.02 (+0.30%)

Barchart Exclusives

This Small AI Infrastructure Company Is Landing Billion-Dollar Contracts Barchart - 1 hour ago
Applied Digital offers the combination of billion-dollar contracts and decades-long revenue visibility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.